HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management.

AuthorsOdile Picard, Patrice Cacoub
JournalClinics and research in hepatology and gastroenterology (Clin Res Hepatol Gastroenterol) Vol. 36 Issue 5 Pg. 437-40 (Oct 2012) ISSN: 2210-741X [Electronic] France
PMID22483956 (Publication Type: Journal Article, Review)
Chemical References
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir
  • N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
  • Proline
Topics
  • Drug Eruptions (etiology)
  • Genotype
  • Hepacivirus (genetics)
  • Hepatitis C (drug therapy)
  • Humans
  • Oligopeptides (adverse effects)
  • Proline (adverse effects, analogs & derivatives)
  • Protease Inhibitors (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: